United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis
Approximately 200,000 patients in the United States have PPF, with limited treatment options Topline data expected in the second half of 2027 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., August 17, 2026--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced full enrollment of its TETON-PPF …
Sharemaestro market context Price below Trend Line 52 weeks +53.0% · Next-week setup negative 21.3%